EA202091857A1 - Новые низкомолекулярные лекарственные коньюгаты производных гемцитабина - Google Patents

Новые низкомолекулярные лекарственные коньюгаты производных гемцитабина

Info

Publication number
EA202091857A1
EA202091857A1 EA202091857A EA202091857A EA202091857A1 EA 202091857 A1 EA202091857 A1 EA 202091857A1 EA 202091857 A EA202091857 A EA 202091857A EA 202091857 A EA202091857 A EA 202091857A EA 202091857 A1 EA202091857 A1 EA 202091857A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hemcitabin
derivatives
drug conjugates
new low
molecular drug
Prior art date
Application number
EA202091857A
Other languages
English (en)
Inventor
Стивен Альберт Эверетт
Крейг Алан Коберн
Original Assignee
Маверикс Онколоджи, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Маверикс Онколоджи, Инк. filed Critical Маверикс Онколоджи, Инк.
Publication of EA202091857A1 publication Critical patent/EA202091857A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/24—Post-translational modifications [PTMs] in chemical analysis of biological material hydroxylation

Abstract

Раскрыты соединения формулы (I)или их фармацевтически приемлемая соль, сложный эфир, амид, сольват или стереоизомер, где каждый L, Y1, Y2, Y3, Y4, Y5, Z1, Z2, Z3, Z4, Z5, Z6 и эффектор являются такими, как определено в описании; их композиции, их применения и способы их применения.
EA202091857A 2018-02-02 2019-02-04 Новые низкомолекулярные лекарственные коньюгаты производных гемцитабина EA202091857A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862625779P 2018-02-02 2018-02-02
PCT/US2019/016477 WO2019152911A1 (en) 2018-02-02 2019-02-04 Novel small molecule drug conjugates of gemcitabine derivatives

Publications (1)

Publication Number Publication Date
EA202091857A1 true EA202091857A1 (ru) 2020-12-04

Family

ID=65494546

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091857A EA202091857A1 (ru) 2018-02-02 2019-02-04 Новые низкомолекулярные лекарственные коньюгаты производных гемцитабина

Country Status (13)

Country Link
US (1) US20210380626A1 (ru)
EP (1) EP3746133A1 (ru)
JP (1) JP2021512951A (ru)
KR (1) KR20200118828A (ru)
CN (1) CN112135635A (ru)
AU (1) AU2019216514A1 (ru)
BR (1) BR112020015747A2 (ru)
CA (1) CA3090272A1 (ru)
EA (1) EA202091857A1 (ru)
IL (1) IL276442A (ru)
PH (1) PH12020551178A1 (ru)
SG (1) SG11202007381YA (ru)
WO (1) WO2019152911A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210367A1 (es) * 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
CN114349816A (zh) * 2021-11-30 2022-04-15 青岛博创生物科学研究院 一种基于氨肽酶n/cd13的小分子偶联分子及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2319837C (en) 1998-02-12 2009-10-27 De Montfort University Hydroxylation activated drug release
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
JP6212831B2 (ja) * 2013-12-04 2017-10-18 杭州源昶医薬科技有限公司 ゲムシタビン誘導体、該誘導体を含む組成物及び該誘導体の製薬用途
EP3119795A4 (en) * 2014-03-03 2018-03-14 Nucorion Pharmaceuticals, Inc. Gemcitabine analogs
CN105001291B (zh) * 2014-04-15 2018-12-04 上海知萌生物医药科技有限公司 吉西他滨化学传递前药及其制备方法和应用
CN107295800A (zh) * 2015-02-25 2017-10-24 配体药物公司 吉西他滨衍生物

Also Published As

Publication number Publication date
BR112020015747A2 (pt) 2020-12-08
JP2021512951A (ja) 2021-05-20
EP3746133A1 (en) 2020-12-09
CA3090272A1 (en) 2019-08-08
CN112135635A (zh) 2020-12-25
KR20200118828A (ko) 2020-10-16
IL276442A (en) 2020-09-30
PH12020551178A1 (en) 2021-06-07
SG11202007381YA (en) 2020-08-28
WO2019152911A1 (en) 2019-08-08
US20210380626A1 (en) 2021-12-09
AU2019216514A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
JOP20220155A1 (ar) مشتقات البيرازول مفيدة كعوامل مضادة للسرطان
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
EP4071149A3 (en) Heterocyclic compounds and uses thereof
WO2017019804A3 (en) Compounds and methods for kinase modulation, and indications therefor
GEP20237470B (en) Magl inhibitors
EA201001769A1 (ru) Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы
TN2018000106A1 (en) Farnesoid x receptor modulators
BRPI0614545B8 (pt) composição farmacêutica de liberação controlada, seu processo de produção, forma de dosagem oral com revestimento entérico de pacreatina e uso da mesma
EP2613782A4 (en) INDAZOLE DERIVATIVES AS INHIBITORS OF THE ERK PATHWAY
BRPI0908120A8 (pt) Compostos que são inibidores de erk, composição faramacêutica e uso
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA201990501A1 (ru) Фармацевтическая композиция
EA202091857A1 (ru) Новые низкомолекулярные лекарственные коньюгаты производных гемцитабина
EP3165532A3 (en) Auristatin derivatives, linker-drugs and ligand-drug conjugates
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
AR108237A1 (es) Métodos para preparar ácido obeticólico y derivados de este
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
PH12020551182A1 (en) Small molecule drug conjugates of gemcitabine monophosphate
DOP2020000088A (es) Derivados de piridinona y su uso como inhibidores selectivos de alk–2.
EP3917926A4 (en) IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITION, USE THEREOF
WO2019004980A3 (en) SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE
ZA202203108B (en) Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections
ZA202203106B (en) Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections